FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2209305610> ?p ?o ?g. }

• W2209305610 endingPage "2623" @default.
• W2209305610 startingPage "2623" @default.
• W2209305610 abstract "AACR Annual Meeting-- Apr 12-16, 2008; San Diego, CA2623 A number of HER2 over-expressing breast cancers are resistant to trastuzumab, a monoclonal antibody targeting HER2. Our lab has generated cell lines resistant to trastuzumab (BT474_R and SkBr3_R) by serial passage through trastuzumab. We have shown that resistant lines and resistant primary tumor samples show an overall decrease of HER2 amplicon gene expression. It is known that histone modifications play a role in regulating gene expression. Histone deacetylase inhibitors (HDACi) have the ability to alter gene expression, and their role in novel combination chemotherapy to treat breast cancers is being explored in the clinic currently. We chose to explore the effect of Trichostatin A, an HDACi, on HER2 amplicon gene expression and response to trastuzumab in HER2 overexpressing cell lines. Five commercially available breast cancer cell lines, BT474, SkBr3, MCF7, MD361, and UACC812, and two in vitro generated trastuzumab-resistant breast cancer cells lines (BT474_R and SkBr3_R) were used. Cells were treated with TSA and/or Herceptin and examined for cell viability, morphology, and apoptosis. HER2 amplicon gene expression was examined before and after 1, 4, and 24 hours treatment with 1 uM TSA by qRT-PCR. Acid extraction of histones was performed to confirm TSA induced changes in histone acetylation. All 8 cell lines were sensitive to TSA (IC50 range 51 nM to 330 nM) as demonstrated by cytotoxicity assays. As expected, BT474 and SkBr3 showed sensitivity to trastuzumab while de novo trastuzumab resistant cell lines (MD361, UACC812) and previously generated resistant cell lines showed little or no sensitivity to trastuzumab. In trastuzumab sensitive cell lines, the combination of TSA and trastuzumab led to decreased cell viability, greater than expected with either drug alone. In de novo resistant and secondarily resistant cell lines, TSA treatment enhanced trastuzumab induced growth inhibition. Interestingly, TSA treatment led to a 2-25 fold induction of genes in the HER2 amplicon examined including HER2, PP1RIB1 (DARPP32), GRB7, C17orF37, and STARD3 in both parental and in vitro generated resistant lines. In vitro acquired resistant lines had greater amplicon induction by TSA than parental controls. The induction of HER2 amplicon genes in resistant lines by TSA results in a HER2 amplicon gene expression pattern similar to the gene expression pattern of de novo trastuzumab sensitive cell lines. HDACi are powerful chemotherapeutic agents that will likely play a role in therapy regimens in the future. We have shown that HER2 amplicon gene expression is altered by TSA treatment and that resistant cell lines show increased induction of HER2 amplicon as compared to trastuzumab sensitive cell lines. We have also shown that TSA changes breast cancer cell sensitivity to trastuzumab. Further exploration into the epigenetic mechanisms of trastuzumab resistance and into the application of novel HDACi is warranted." @default.
• W2209305610 created "2016-06-24" @default.
• W2209305610 creator A5013315514 @default.
• W2209305610 creator A5016816358 @default.
• W2209305610 creator A5021514634 @default.
• W2209305610 creator A5077315571 @default.
• W2209305610 creator A5086326461 @default.
• W2209305610 date "2008-05-01" @default.
• W2209305610 modified "2023-09-26" @default.
• W2209305610 title "Epigenetic therapy can rescue trastuzumab resistance in HER2 over-expressing breast cancers." @default.
• W2209305610 hasPublicationYear "2008" @default.
• W2209305610 type Work @default.
• W2209305610 sameAs 2209305610 @default.
• W2209305610 citedByCount "0" @default.
• W2209305610 crossrefType "journal-article" @default.
• W2209305610 hasAuthorship W2209305610A5013315514 @default.
• W2209305610 hasAuthorship W2209305610A5016816358 @default.
• W2209305610 hasAuthorship W2209305610A5021514634 @default.
• W2209305610 hasAuthorship W2209305610A5077315571 @default.
• W2209305610 hasAuthorship W2209305610A5086326461 @default.
• W2209305610 hasConcept C104317684 @default.
• W2209305610 hasConcept C121608353 @default.
• W2209305610 hasConcept C126322002 @default.
• W2209305610 hasConcept C153911025 @default.
• W2209305610 hasConcept C191560914 @default.
• W2209305610 hasConcept C2776202225 @default.
• W2209305610 hasConcept C2776262904 @default.
• W2209305610 hasConcept C2777865847 @default.
• W2209305610 hasConcept C2778305200 @default.
• W2209305610 hasConcept C2779786085 @default.
• W2209305610 hasConcept C2994423619 @default.
• W2209305610 hasConcept C502942594 @default.
• W2209305610 hasConcept C530470458 @default.
• W2209305610 hasConcept C54355233 @default.
• W2209305610 hasConcept C64927066 @default.
• W2209305610 hasConcept C71924100 @default.
• W2209305610 hasConcept C86803240 @default.
• W2209305610 hasConceptScore W2209305610C104317684 @default.
• W2209305610 hasConceptScore W2209305610C121608353 @default.
• W2209305610 hasConceptScore W2209305610C126322002 @default.
• W2209305610 hasConceptScore W2209305610C153911025 @default.
• W2209305610 hasConceptScore W2209305610C191560914 @default.
• W2209305610 hasConceptScore W2209305610C2776202225 @default.
• W2209305610 hasConceptScore W2209305610C2776262904 @default.
• W2209305610 hasConceptScore W2209305610C2777865847 @default.
• W2209305610 hasConceptScore W2209305610C2778305200 @default.
• W2209305610 hasConceptScore W2209305610C2779786085 @default.
• W2209305610 hasConceptScore W2209305610C2994423619 @default.
• W2209305610 hasConceptScore W2209305610C502942594 @default.
• W2209305610 hasConceptScore W2209305610C530470458 @default.
• W2209305610 hasConceptScore W2209305610C54355233 @default.
• W2209305610 hasConceptScore W2209305610C64927066 @default.
• W2209305610 hasConceptScore W2209305610C71924100 @default.
• W2209305610 hasConceptScore W2209305610C86803240 @default.
• W2209305610 hasLocation W22093056101 @default.
• W2209305610 hasOpenAccess W2209305610 @default.
• W2209305610 hasPrimaryLocation W22093056101 @default.
• W2209305610 hasRelatedWork W1525807619 @default.
• W2209305610 hasRelatedWork W1995407080 @default.
• W2209305610 hasRelatedWork W1997381761 @default.
• W2209305610 hasRelatedWork W2022334033 @default.
• W2209305610 hasRelatedWork W2071603445 @default.
• W2209305610 hasRelatedWork W2158927987 @default.
• W2209305610 hasRelatedWork W2316286037 @default.
• W2209305610 hasRelatedWork W2317147303 @default.
• W2209305610 hasRelatedWork W2318101903 @default.
• W2209305610 hasRelatedWork W2318960175 @default.
• W2209305610 hasRelatedWork W2410078130 @default.
• W2209305610 hasRelatedWork W2562564824 @default.
• W2209305610 hasRelatedWork W2567562590 @default.
• W2209305610 hasRelatedWork W2921963807 @default.
• W2209305610 hasRelatedWork W2944792939 @default.
• W2209305610 hasRelatedWork W2955475115 @default.
• W2209305610 hasRelatedWork W2968884715 @default.
• W2209305610 hasRelatedWork W3137539178 @default.
• W2209305610 hasRelatedWork W34965712 @default.
• W2209305610 hasRelatedWork W986140772 @default.
• W2209305610 hasVolume "68" @default.
• W2209305610 isParatext "false" @default.
• W2209305610 isRetracted "false" @default.
• W2209305610 magId "2209305610" @default.
• W2209305610 workType "article" @default.